1. Home
  2. NICE vs DFTX Comparison

NICE vs DFTX Comparison

Compare NICE & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NICE Ltd

NICE

NICE Ltd

HOLD

Current Price

$91.60

Market Cap

5.6B

Sector

Technology

ML Signal

HOLD

Logo Definium Therapeutics Inc. Common Shares

DFTX

Definium Therapeutics Inc. Common Shares

SELL

Current Price

$29.20

Market Cap

5.9B

Sector

N/A

ML Signal

SELL

Company Overview

Basic Information
Metric
NICE
DFTX
Founded
1986
N/A
Country
Israel
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
5.6B
5.9B
IPO Year
1999
2020

Fundamental Metrics

Financial Performance
Metric
NICE
DFTX
Price
$91.60
$29.20
Analyst Decision
Buy
Strong Buy
Analyst Count
14
19
Target Price
★ $127.54
$72.83
AVG Volume (30 Days)
569.0K
★ 1.5M
Earning Date
11-04-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$7.91
N/A
Revenue Next Year
$7.78
N/A
P/E Ratio
$11.21
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$83.10
$14.62
52 Week High
$135.55
$49.70

Technical Indicators

Market Signals
Indicator
NICE
DFTX
Relative Strength Index (RSI) 27.87 34.77
Support Level $86.27 $20.43
Resistance Level $104.84 $37.72
Average True Range (ATR) 3.97 2.14
MACD -1.55 -0.39
Stochastic Oscillator 10.68 6.45

Price Performance

Historical Comparison
NICE
DFTX

About NICE NICE Ltd

Nice is an enterprise software company that serves the customer engagement and financial crime and compliance markets. Software is deployed primarily on the cloud, but also on premises. Within customer engagement, Nice's CXone is the leading CCaaS platform providing solutions such as call routing, interactive voice response, digital self-service, and workforce engagement management. Within financial crime and compliance, Nice offers risk and investigation management, fraud prevention, anti-money-laundering, and compliance solutions.

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.

Share on Social Networks: